EGFR Tyrosine Kinase Inhibitors and Brain Metastases

EP: 1.Lung Cancer: Molecular Testing

EP: 2.Mobocertinib for NSCLC With EGFR Exon 20 Insertion Mutations

EP: 3.Adverse Events Associated With Mobocertinib

EP: 4.New Therapies in Non–Small Cell Lung Cancer

EP: 5.Unmet Needs in Non–Small Cell Lung Cancer

EP: 6.Targeted Therapy for Metastatic Non–small Cell Lung Cancer

EP: 7.Non–small Cell Lung Cancer With EGFR Exon 20 Insertion

EP: 8.EGFR Exon 20–Directed Therapy With Mobocertinib

Now Viewing

EP: 9.EGFR Tyrosine Kinase Inhibitors and Brain Metastases

EP: 10.Mobocertinib’s Safety Profile

EP: 11.New Therapies for NSCLC With EGFR Exon 20 Insertions

EP: 12.EGFR Mutation Heterogeneity

Mark A. Socinski, MD: One of the issues in the EGFR mutation–positive population is the issue of brain metastases, either at the time of diagnosis or at some point during the course of their disease. We know that some of the EGFR TKIs [tyrosine kinase inhibitors], drugs like osimertinib have very good CNS [central nervous system] penetration. We have a host of drugs being developed in the exon 20 insertion mutation–positive population, in which the early data suggest there’s some degree of activity. We’ve certainly seen that with mobocertinib, as well as a few others. I think about how confident we are about the CNS activity, and it’s still a little early to tell at this point. I think we can say that there clearly is activity in select patients. What the numerator and denominator are at this point is unclear, and we need some more time to sort these things out before we really know how confident we can be that drugs like mobocertinib really do have substantial and equivalent activity in the CNS like they do in extra CNS sites.

TRANSCRIPT EDITED FOR CLARITY